Posaconazole Treatment in Korea: Single-Center Experience Over 5 Years
3
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Posaconazole is a second-generation triazole with a broad spectrum. However, there is a lack of data to support a significant role for posaconazole in the treatment of invasive fungal infection (IFI), especially in Korea. Until recently, posaconazole was available only through the Korean Orphan Drug Center. This study was designed to review the use of posaconazole at a single-center in Korea. Materials and Methods: Data from patients who received posaconazole treatment at Catholic Blood and Marrow Transplantation Center were retrospectively reviewed between January 2007 and September 2012. Results: A total of 11 cases (3 males and 8 females, median age 52 years) received posaconazole. Five patients were given the drug for mucormycosis, two for invasive aspergillosis, and four for unspecified IFI for which galactomannan (GM) assays were negative. The treatment duration ranged from 4-250 days. Three patients received posaconazole for management refractory IFI, two for intolerance of previous antifungal therapy, and six for long-term maintenance treatment. The overall successful response rate to posaconazole was 55% (six of eleven patients). Five of eleven patients died during the study period. However, only one death was attributed to the progression of IFI. None of the patients discontinued posaconazole therapy due to adverse events. Conclusion: Posaconazole is an attractive oral antifungal agent for salvage treatment of IFI, particularly upon diagnosis of mucormycosis or in cases in which mucormycosis cannot be ruled out due to a negative GM.
Abstract
Purpose: Posaconazole is a second-generation triazole with a broad spectrum. However, there is a lack of data to support a significant role for posaconazole in the treatment of invasive fungal infection (IFI), especially in Korea. Until recently, posaconazole was available only through the Korean Orphan Drug Center. This study was designed to review the use of posaconazole at a single-center in Korea. Materials and Methods: Data from patients who received posaconazole treatment at Catholic Blood and Marrow Transplantation Center were retrospectively reviewed between January 2007 and September 2012. Results: A total of 11 cases (3 males and 8 females, median age 52 years) received posaconazole. Five patients were given the drug for mucormycosis, two for invasive aspergillosis, and four for unspecified IFI for which galactomannan (GM) assays were negative. The treatment duration ranged from 4-250 days. Three patients received posaconazole for management refractory IFI, two for intolerance of previous antifungal therapy, and six for long-term maintenance treatment. The overall successful response rate to posaconazole was 55% (six of eleven patients). Five of eleven patients died during the study period. However, only one death was attributed to the progression of IFI. None of the patients discontinued posaconazole therapy due to adverse events. Conclusion: Posaconazole is an attractive oral antifungal agent for salvage treatment of IFI, particularly upon diagnosis of mucormycosis or in cases in which mucormycosis cannot be ruled out due to a negative GM.
참고문헌 (24)
- Mullane K, "Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections", Transpl Infect Dis, 9, pp.89~96 (2007)
- Rachwalski EJ, "Posaconazole: an oral triazole with an extended spectrum of activity", Ann Pharmacother, 42, pp.1429~1438 (2008)
- Greenberg RN, "Posaconazole as salvage therapy for zygomycosis", Antimicrob Agents Chemother, 50, pp.126~133 (2006)
- Nagappan V, "Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent", Clin Infect Dis, 45, pp.1610~1617 (2007)
- Morris MI, "Posaconazole: a new oral antifungal agent with an expanded spectrum of activity", Am J Health Syst Pharm, 66, pp.225~236 (2009)
- De Pauw B, "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer", Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC, Clin Infect Dis, pp.2008, 46[DOI]
- Segal BH, "Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria", Clin Infect Dis, 47, pp.674~683 (2008)
- Raad II, "Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions", Clin Infect Dis, 42, pp.1398~1403 (2006)
- 이동건, "Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea", The Korean Journal of Internal Medicine, 26(2), pp.220~252 (2011), 대한내과학회
- Common terminology criteria for adverse events (CTCAE) v4.0, , National Cancer Institute, ~ (2009)
- 윤영경, "Successful Treatment of a Case with Rhino-Orbital- Cerebral Mucormycosis by the Combination of Neurosurgical Intervention and the Sequential Use of Amphotericin B and Posaconazole", 대한신경외과학회지, 47(1), pp.74~78 (2010), 대한신경외과학회
- 김우재, "털곰팡이증: Amphotericin B 치료 실패 후 Posaconazole로 호전된 1예", 대한내과학회지, 79(5), pp.587~591 (2010), 대한내과학회
- Alastruey-Izquierdo A, "In vitro activity of antifungals against Zygomycetes", Clin Microbiol Infect, 15(5), pp.71~76 (2009)
- Cornely OA, "Current experience in treating invasive zygomycosis with posaconazole", Clin Microbiol Infect, 15(5), pp.77~81 (2009)
- Almyroudis NG, "In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents", Antimicrob Agents Chemother, 51, pp.2587~2590 (2007)
- Raad II, "Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin", Leukemia, 22, pp.496~503 (2008)
- Traunmüller F, "Efficacy and safety of current drug therapies for invasive aspergillosis", Pharmacology, 88, pp.213~224 (2011)
- Walsh TJ, "Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial", Clin Infect Dis, 44, pp.2~12 (2007)
- Greer ND, "Posaconazole (Noxafil): a new triazole antifungal agent", Proc (Bayl Univ Med Cent), 20, pp.188~196 (2007)
- van Burik JA, "Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases", Clin Infect Dis, 42, pp.e61~e65 (2006)
- Krishnan-Natesan S, "A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro", Diagn Microbiol Infect Dis, 63, pp.361~364 (2009)
- Kontoyiannis DP, "Invasive mycoses: strategies for effective management", Am J Med, 125(1), pp.S25~S38 (2012)
- Bhattacharya M, "Posaconazole", J Postgrad Med, 56, pp.163~167 (2010)
- Raad II, "Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections", Clin Infect Dis, 42, pp.1726~1734 (2006)